Home

Novartis Venture Fund

Novartis Venture Fund

We have taken over 70 companies to a successful exit since setting up the Novartis Venture Fund in 1996 – that is three on average per year. These exits have primarily resulted in IPOs and M&As, with several drugs receiving FDA approval. Nearly 40 companies completed initial public offerings (IPO) Over 30 progressed to a merger and acquisition by a number of top pharmaceutical companies.
Investor Type:
VC Firm
HQ Location:
Switzerland
Investment Areas:
Finance, Therapeutics, Venture Capital, Life Science, Investment
Typical Investment:
Above €3M
Funding Stage:
Pre-Seed / Seed, Series A/B, Series C & Beyond
Linkedin:
Contact Email:
[email protected]